Publication Date: 2022/12/10
Abstract: Obesity and diabetes prevalence are often referred to as the "twin epidemics" and are becoming a more widespread issue, particularly in developed countries. Advanced therapeutic strategies are therefore required. Tirzepatide, known as "twincretin", is a "firstclass" drug and the only agonist of glucagon-like peptide1 (GLP-1) and glucose-dependent peptide (GIP) receptors, which can significantly reduce blood sugar. levels and improved insulin sensitivity, as well as more than 20% reduction in body weight and improved lipid metabolism. This new antidiabetic drug is a synthetic peptide analog of human GIP hormone with a linkage to C20 fatty acid moiety that, through acylation process, can bind to albumin to deliver a single dose, by a single subcutaneous injection, once a week, consistent with its half-life of approximately five days. The "twincretin" heralded in an era of tremendously important and alluring dual therapy choices for diabetes and obesity, as well as advanced management of closely associated cardiometabolic settings, which are the primary global cause of illness, disability, and mortality. Here, we outline the salient features of tirzepatide's synthesis, structure, and action while also considering its benefits and drawbacks. Additionally, we briefly examine the progression of clinical research and the evolution of this type of medicinal medication.
Keywords: Diabetes, Insulin, Incretins, Obesity, Tirzepatide, Twincretin.
DOI: https://doi.org/10.5281/zenodo.7420605
PDF: https://ijirst.demo4.arinfotech.co/assets/upload/files/IJISRT22NOV1239.pdf
REFERENCES